VistaGen Therapeutics, Inc.VTGNNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-28.63%
↓ 96% below average
Average (39q)
-14.64%
Historical baseline
Range
High:76.86%
Low:-296.05%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -28.63% |
| Q2 2025 | -10.71% |
| Q1 2025 | 3.22% |
| Q4 2024 | -8.70% |
| Q3 2024 | -20.76% |
| Q2 2024 | -12.73% |
| Q1 2024 | -49.95% |
| Q4 2023 | 3.62% |
| Q3 2023 | 4.56% |
| Q2 2023 | 43.54% |
| Q1 2023 | -25.26% |
| Q4 2022 | 44.17% |
| Q3 2022 | 11.60% |
| Q2 2022 | -18.50% |
| Q1 2022 | -58.41% |
| Q4 2021 | 17.66% |
| Q3 2021 | -65.21% |
| Q2 2021 | -24.69% |
| Q1 2021 | -17.22% |
| Q4 2020 | -60.67% |
| Q3 2020 | -5.47% |
| Q2 2020 | 4.28% |
| Q1 2020 | 45.20% |
| Q4 2019 | -11.72% |
| Q3 2019 | 14.07% |
| Q2 2019 | -8.50% |
| Q1 2019 | 20.69% |
| Q4 2018 | 2.93% |
| Q3 2018 | -76.41% |
| Q2 2018 | -3.33% |
| Q1 2018 | -35.74% |
| Q4 2017 | 39.87% |
| Q3 2017 | -120.59% |
| Q2 2017 | 11.12% |
| Q1 2017 | 3.40% |
| Q4 2016 | 14.92% |
| Q3 2016 | -57.65% |
| Q2 2016 | 76.86% |
| Q1 2016 | -296.05% |
| Q4 2015 | 69.54% |